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Abstract  
Introduction: Health-related quality of life (HRQoL) is a patient-reported outcome that 
addresses patients’ perceptions of symptoms across physical, emotional, cognitive and social 
domains. As HRQoL is currently rarely measured outside clinical trials in oncology, it must 
be inferred from patients’ everyday performance during treatment. To gain insight into the 
HRQoL of advanced STS patients receiving palliative treatment in clinical practice, three 
case studies of patients treated with trabectedin are examined.  
Areas covered: The patient in Case 1 has maintained complete remission for more than 8 
years after receiving 9 cycles of second-line trabectedin followed by secondary surgery for 
recurrent myxoid liposarcoma, and was able to resume normal activities during trabectedin 
treatment. Case 2 describes 10 years’ follow-up of a patient with myxoid liposarcoma who 
remains well after many lines of chemotherapy including extended use of trabectedin in the 
second line. The third case illustrates the feasibility of extending survival time in an elderly 
patient with metastatic leiomyosarcoma who was able to maintain a busy and active lifestyle 
while receiving second-line trabectedin. 
Expert commentary: Owing to its relatively benign safety profile, trabectedin frequently 
permits prolonged therapy and is generally well tolerated, often allowing patients to carry on 
with normal daily activities. 
 
 
Key words: health-related quality of life; soft tissue sarcomas; trabectedin 
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1. Introduction 
Disease management is increasingly becoming patient-centric. A patient’s own report of a 
response to treatment or health care that is not subject to interpretation by a clinician or 
healthcare professional is known as a patient-reported outcome (PRO). PROs typically deal 
with aspects of the patient’s health, functional status or quality of life (QoL) [1]. An 
important PRO in the oncological setting is health-related quality of life (HRQoL) which 
addresses patients’ perceptions of symptoms across physical, emotional, cognitive and social 
domains [2,3]. HRQoL data, along with sociodemographic variables and clinical measures, 
are prognostic indicators for overall survival in a range of cancers [3−5]. 
Multiple instruments, either disease-specific or generic, have been used to measure HRQoL 
in oncology. The cancer-specific European Organization for Research and Treatment of 
Cancer 30-item core QoL questionnaire (EORTC QLQ-C30) [7] is widely used, for example 
by Quinten and colleagues [3−5], to demonstrate the prognostic value of HRQoL domain 
data. For patients with soft tissue sarcomas (STS) and extremity bone sarcomas, the Toronto 
Extremity Salvage Score (TESS) is a disease-specific PRO to evaluate physical function [8]. 
Generic instruments used to assess HRQoL in cancer patients include the 36-item Short Form 
36 (SF-36) [9]. A standardized instrument for measuring generic health status is the five-
dimensional instrument (EQ-5D) developed by the EuroQol Group. Alongside condition-
specific PROs, there is growing use of the EQ-5D as part of routine, administrative data 
collection in healthcare systems to generate real-world insights into treatment and provider 
effectiveness [11].   
Although only few studies in patients with sarcomas have included QoL as an endpoint, they 
indicate that HRQoL deteriorates with disease progression. In patients with metastatic STS or 
bone sarcomas, application of the EORTC QLQ-C30 and EQ-5D instruments showed that 
disease progression had a significant negative impact on HRQoL, with patients receiving 
second-line treatment reporting lower health utility than those receiving first-line therapy 
[12]. Application of the EORTC QLQ-C30 tool in the PALETTE trial for patients with 
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advanced STS receiving pazopanib or placebo for second-line or later therapy showed no 
statistically significant between-group differences in QOL-C30 global health status and a 
trend towards a decline in mean global health status over time in both treatment arms [13]. In 
the randomized phase III SAR-3007 trial comparing trabectedin and dacarbazine in patients 
with advanced leiomyosarcoma or liposarcoma [14], patients completed the MD Anderson 
Symptom Inventory, a self-reported 19-item questionnaire that captures experience across 13 
symptom measures and six measures of physical and mental functions. No clinically 
meaningful differences between treatment arms were observed, although symptom burden at 
baseline was relatively low and minimal symptom and functional interference was 
maintained for the duration of both treatments. 
HRQoL is rarely formally measured in oncology clinical studies, and much less frequently if 
at all in routine clinical practice. In clinical practice, patients’ QoL must be inferred by other 
means such as their everyday performance during or after local or systemic treatment.  
Chemotherapy is the mainstay of treatment for patients with advanced or metastatic STS. 
Selecting the best chemotherapeutic regimen for an individual patient requires evaluation of 
various patient- and tumor-related factors as well as the patient’s goals and expectations of 
treatment [15]. Certain clinical situations demand an aggressive treatment approach to reduce 
tumor burden or alleviate symptoms, whereas other situations call for a palliative approach 
with the aims of long-term disease control and preservation of QoL [15]. To gain insight into 
the QoL of patients with advanced STS receiving chemotherapy in routine clinical practice, 
we present three case studies of patients treated with trabectedin in the second line, with a 
focus on patients’ ability to perform usual daily activities under treatment.  
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2. Case studies 
2.1 . Case 1 
In July 2008, a 23-year-old female presented a bulky mediastinal and intra-thoracic right side 
tumor manifested by dyspnea and weight loss. Diagnosis was grade (G) 1 myxoid 
liposarcoma. Three cycles of neoadjuvant doxorubicin + ifosfamide led to stable disease but 
with severe associated adverse effects, mainly febrile neutropenia. Computed tomography 
(CT) scans showed a mixed (fat + fleshy) lesion in the right thoracic hemisphere with a left 
side mediastinal shift (Figure 1). Following agreement by surgeons that complete resection 
was feasible in this patient, R0 surgery was performed followed by adjuvant radiotherapy 50 
Gy / 25 fraction which was standard protocol at the time of treatment. In September 2009 (6 
months after adjuvant radiotherapy), the patient had a symptomatic intrathoracic recurrence 
confirmed by biopsy. Trabectedin commenced at a dose of 1.5 mg/m2 although had to be 
reduced due to elevated liver enzymes (10 × upper limit of normal); bilirubin remained 
normal and clinical symptoms were absent. Major clinical improvement was observed during 
trabectedin treatment and, in the absence of symptomatic adverse events, the patient was able 
to resume normal activities. After 9 cycles of trabectedin, CT scan showed complete 
remission of the first lesion and a major response in the second lesion in the right lobe of the 
thymus (Figure 2). Positron-emission tomography (PET) indicated no disease activity. In 
May 2010, the thymus was surgically resected. Pathological examination indicated no tumor 
cells and only fibrosis. For 8 years since, the patient has undergone regular surveillance with 
no signs of recurrence.  
 
2.2. Case 2 
Case 2 involves a male patient aged 37 years at the time of diagnosis (July 2008) with 
antecedents of an appendectomy in 1987. He was diagnosed with a 10 cm soft tissue tumor 
located in the thoracic wall, in the right posterior costophrenic sinus. Core needle biopsy 
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indicated myxoid liposarcoma. A right thoracotomy was performed on 31 July 2008. 
Pathology was reported as a G2 myxoid liposarcoma, 10 × 7 × 3 cm in size, with vascular 
invasion. Resection was marginal. Post-surgery, the patient received external radiotherapy 
combined with brachytherapy in the thoracic wall (66 Gy).  
CT scan in December 2011 detected a right apical pulmonary mass which was confirmed by 
biopsy as relapsed myxoid liposarcoma. In February 2012, the patient underwent surgical 
resection by cervico-sterno-thoracotomy. Pathology indicated G2 myxoid liposarcoma, 6 cm 
in diameter. Post-operative radiation (66 Gy) was administered.  
In March 2013, the patient presented a right paratracheal mediastinal mass of 4 cm, a right 
paravertebral retrocrural mass of 6.6 cm and four liver metastases (the largest being 2.8 cm). 
He was enrolled in the phase III randomized clinical trial of doxorubicin ± evofosfamide 
(TH-CR-406) [16], and allocated to doxorubicin 75 mg/m2 monotherapy which commenced 
in April 2013. Several episodes of G4 neutropenia, without associated fever, necessitated 
delay of subsequent cycles to every 4 weeks instead of every 3 weeks. After 2 cycles of 
doxorubicin, stable disease was observed and, after 4 cycles, CT scan showed a partial 
response. The patient completed 6 cycles of chemotherapy in July 2013.  
In July 2014 the patient presented with progression of the retrocrural lesion (9 cm) and liver 
metastases, the largest being 2.1 cm. Treatment commenced with trabectedin 1.5 mg/m2 in a 
24 h infusion every 3 weeks, with good tolerability. Adverse events were limited to mild 
asthenia, sporadic nausea, and asymptomatic G3 neutropenia which was managed by 
administering prophylactic granulocyte-colony stimulating factor (G-CSF) for 5 days in 
subsequent cycles. During treatment, he maintained an active life, taking care of his two 
young children and travelling with them between cycles. After four cycles of trabectedin, a 
CT scan showed a partial response in the liver metastases and retrocrural mass. CT images 
before and after 6 cycles of trabectedin are shown in Figure 3. Ten cycles of trabectedin were 
delivered, ending in April 2015. During the two last cycles, asthenia worsened (still G1 but 
more prolonged). The patient was weary of chemotherapy and requested a break. The partial 
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response was maintained until February 2016, when a CT scan showed an increase in the size 
of the liver metastases (largest 4.5 cm) and retrocrural lesion. Trabectedin rechallenge (1.5 
mg/m2 in 24 h) commenced and 6 cycles were delivered, ending in August 2016 due to 
worsening asthenia. Treatment was well tolerated, although asymptomatic G3 neutropenia 
despite prophylactic G-CSF led to frequent 1-week delays in administration of the next cycle. 
After 3 cycles of trabectedin, a CT scan revealed a new partial response which was 
maintained until January 2017. CT images pre- and post-rechallenge with trabectedin (6 
cycles) are shown in Figure 4.  
There was no response to third-line therapy with gemcitabine + dacarbazine (× 3 months). 
Eribulin led to stable disease but treatment was stopped after 3 cycles due to polyneuropathy; 
disease progressed within 3 months. Ifosfamide was initiated and was ongoing at the time of 
writing.  
 
2.3. Case 3 
Case 3 involves a 65-year-old female patient who presented in June 2013 to her general 
practitioner with diffuse intra-abdominal pain. Initially the pain occurred only in the morning 
but worsened over ensuing months; at first presentation to hospital it was described as 
occurring after every meal. Symptoms such as night sweats, weight loss or loss of appetite 
were absent. Medical history included arterial hypertension, hypothyroidism and a tubal 
pregnancy more than 30 years ago. She had no history of a previous serious illness, nor any 
intra-abdominal operations.  
A thoracic and abdominal CT scan showed a large (13.5 × 12.0 × 10 cm) right retroperitoneal 
mass presumably related to the adrenal gland. Liver infiltration was suggested, and two 
suspicious intrapulmonary lesions were described. Ultrasound-guided core needle biopsy led 
to a diagnosis of a G2 (French Federation of Comprehensive Cancer Centers) 
leiomyosarcoma.  
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Explorative laparoscopy identified three small, previously unknown liver lesions which were 
diagnosed as metastases by instantaneous section. Infiltration of the caudate lobe precluded 
opportunity for a reasonable tumor resection. 
Following the patient’s recovery from surgery, first-line doxorubicin 75 mg/m2 was 
administered every 3 weeks for 6 cycles. G-CSF support was required after the third cycle 
due to a low neutrophil count. The doxorubicin dose was reduced to 60 mg/m2 for the last 2 
cycles due to worsening of her general condition, especially asthenia and progressive 
thrombocytopenia. She tolerated doxorubicin reasonably well and, after 6 cycles, the 
unresectable intra-abdominal tumor was reduced in size to 9.0 cm. Fractionated radiotherapy 
(total dose of 54 Gy) given to consolidate the tumor was well tolerated.  
A follow-up CT scan a year later showed growing intrahepatic and intrapulmonary 
metastases although, clinically, the patient was in good condition. Second-line trabectedin 
was initiated and 12 cycles were delivered. Pulmonary metastases during and at the end of 
trabectedin therapy are shown in Figure 5. The trabectedin dose had to be reduced gradually 
from 1.5 mg/m2 (24 h) to 1.0 mg/m2 (24 h) due to elevated liver enzymes (>10 × upper limit 
of normal), although bilirubin remained normal and clinical symptoms were absent. G-CSF 
support due to transient afebrile G4 neutropenia was required for cycles in which the 
trabectedin dose was above 1.0 mg/m2. The best outcome under trabectedin was stable 
disease. During the entire course of therapy, the patient maintained normal daily activities: 
she managed the household, cared for herself, looked after her grandchildren, travelled in her 
mobile home for holidays, went on bicycle tours; and managed support services for her 
mother who had also been diagnosed with sarcoma.  
After 12 cycles of trabectedin, the patient presented again with growing intrahepatic and 
intrapulmonary metastases while the irradiated intra-abdominal tumor remained stable. Third-
line therapy with pazopanib was started but stopped when she developed an acute infarction 
of the medial cerebral artery with transient paresis of her right hand. As the patient remained 
in reasonably good general health she agreed to fourth-line therapy with gemcitabine + 
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dacarbazine. After two cycles, the tumor progressed with rapid onset of growing intrahepatic 
and intrapulmonary lesions, as well as diffuse intramuscular and subcutaneous metastases. As 
her general condition deteriorated quickly, the therapeutic strategy was switched to best 
supportive care. The patient died 28 months after first diagnosis of leiomyosarcoma. Figure 6 
shows an intra-abdominal mass and liver metastases during and at the end of treatment with 
trabectedin, and under third-line (pazopanib) and fourth-line (gemcitabine + dacarbazine) 
therapy. 
 
3. Expert commentary 
Consistent with the results of previous phase II [17] and phase III [18] clinical trials and real-
life studies [19−21] reporting on second-line use of trabectedin in advanced liposarcoma and 
leiomyosarcoma, trabectedin showed good efficacy in these patients. To provide some 
perspective on the distinguishing features of trabectedin in the palliative setting in advanced 
sarcoma, key elements of each case are summarized below.  
The patient in Case 1 received 9 cycles of second-line trabectedin followed by secondary 
surgery for a recurrent G1 myxoid liposarcoma, achieving a complete response in one lesion 
and a major response in the other lesion which facilitated curative surgery (Figure 7). In the 
absence of symptomatic adverse events, she was able to resume normal activities, although a 
dose reduction was r quired due to the presence of elevated liver enzymes [22]. Transient 
elevations in alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) tend 
to be more common during the first two cycles of trabectedin then decline in subsequent 
cycles and, as indicated, can be managed with dose reductions [17,18,21].  
In Case 2, standard first-line doxorubicin monotherapy for metastatic myxoid liposarcoma 
produced a partial response despite 1-week delays in the dosing interval due to G4 
neutropenia. At recurrence, treatment commenced with second-line trabectedin which was 
mainly well tolerated with G-CSF support for asymptomatic G3 neutropenia. The patient 
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maintained an active life during treatment including taking care of two young children. Ten 
cycles of trabectedin were administered, resulting in a partial response after 4 cycles and a 
progression-free interval of approximately 19 months. Trabectedin rechallenge (× 6 cycles) at 
recurrence resulted in a new partial response. Clinical benefit with trabectedin rechallenge 
has been reported in patients with responding myxoid liposarcomas [23]. Around the time 
that the patient had completed his first course of trabectedin, it was reported that treatment 
continuation is superior to treatment interruption in terms of 6-month progression-free 
survival (51.9 vs 23.1%; p = 0.02) in patients with advanced doxorubicin-refractory STS who 
have not progressed after receiving 6 cycles of trabectedin [24]. Nevertheless, despite the 
treatment interruption, the patient achieved a new partial response to trabectedin rechallenge 
which was maintained for approximately 9 months. He remains alive approximately 10 years 
after initial diagnosis (Figure 8).   
Case 3 illustrates the feasibility of extending survival time in an elderly patient with 
metastatic leiomyosarcoma (Figure 9). Standard first-line doxorubicin therapy resulted in a 
partial response, although G-CSF support and dose reductions were required to manage 
various toxicities. At disease recurrence, second-line treatment with trabectedin commenced 
which was maintained for 12 cycles. Adverse events were managed by dose reductions and 
G-CSF support as required. During trabectedin treatment, the patient maintained an active 
and busy lifestyle including managing her own affairs as well as support services for her 
seriously ill mother. A retrospective pooled analysis of phase II trials of trabectedin involving 
350 STS patients indicated that trabectedin is a feasible option regardless of patient age (< 60 
years, ≥ 60 years), providing meaningful clinical benefit with an acceptable and manageable 
safety profile [25]. 
For most patients with refractory STS, the main therapeutic goal is long-term disease 
stabilization with good QoL [15]. Collectively, these case studies highlight several features of 
trabectedin that set it apart from other chemotherapeutic agents for palliative treatment of 
advanced STS. The relatively benign safety profile of trabectedin compared with other 
chemotherapeutic agents frequently allows for prolonged treatment and makes trabectedin 
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suitable for use in the elderly. Adverse effects that do occur with trabectedin can generally be 
readily managed with dose reductions and G-CSF support. In the event of treatment 
interruption (e.g. a patient requests a ‘drug holiday’), trabectedin rechallenge is a feasible and 
effective approach. During treatment with trabectedin, many patients are able to carry out 
normal daily activities, with inferred less detriment to their HRQoL compared with other 
chemotherapeutic options for use in advanced sarcoma. Indeed, until such time as PROs are 
integrated into daily clinical practice, a few simple questions about a patient’s everyday life 
might serve as a useful surrogate measure of HRQol. Importantly, the good tolerability of 
trabectedin does not come at the cost of compromised efficacy as patients can benefit from an 
active treatment capable of producing prolonged stable disease.   
 
 
4. Five-year view 
In the palliative setting of advanced STS, understanding the effectiveness of treatment from a 
patient’s perspective is essential to inform the selection of options that adequately address 
his/her individual needs. As such, interest in incorporating PROs into clinical research and 
routine practice is growing. PRO provide first-hand insight into patients’ health status, 
treatment satisfaction, well-being, and HRQoL.  
Leading the way in this regard is YonLife (ClinicalTrials.gov identifier: NCT02204111), a 
prospective study designed to explore the effect of a multidisciplinary expert consensus on 
QoL in patients with metastatic STS [26,27]. The study involved seven sites in Germany and 
was completed in September 2017. Adult patients under treatment with trabectedin were 
randomized to receive multidimensional intervention or usual supportive treatment (control 
group). The intervention group received individualized treatment proposals compiled by an 
expert panel based on a patient’s self-assessed HRQoL using a standard online questionnaire 
(FACT-G) and supplemented with clinical data derived from the patient file. Despite 
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methodological uncertainties regarding the choice of PROs for assessment as well as the 
practicality of proposing treatment for patients not encountered in person, this ambitious 
study has the potential to provide a platform for future patient-directed research. At 
minimum, the study will provide greater insight into HRQoL in patients with advanced STS 
receiving treatment with trabectedin. The results are awaited with interest. 
 
Key issues 
A patient’s own report of a response to treatment or health care that is not subject to 
interpretation by a clinician or healthcare professional is known as a patient-reported outcome 
(PRO).  
PROs typically deal with aspects of a patient’s health, functional status or health-related 
quality of life (HRQoL).  
HRQoL is rarely formally measured in oncology clinical studies and much less so in clinical 
practice; thus, it must be inferred by other means such as the ability of a patient to carry out 
usual daily activities during or after treatment.  
This review presents three case studies of patients with advanced STS under treatment with 
trabectedin.  
The patient in Case 1 has maintained complete remission for more than 8 years after 
receiving 9 cycles of second-line trabectedin followed by secondary surgery for a recurrent 
myxoid liposarcoma. In the absence of symptomatic adverse events during trabectedin 
treatment, she was able to resume normal activities.  
The second case describes 10 years’ follow-up of a patient with myxoid liposarcoma who 
remains well after many lines of chemotherapy. He achieved partial responses during second-
line treatment with trabectedin and subsequent rechallenge and maintained an active life 
during treatment. 
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The third case illustrates the feasibility of extending survival time with trabectedin in an 
elderly patient with metastatic leiomyosarcoma. During the entire course of trabectedin (12 
cycles), the patient was able to maintain a busy and active lifestyle.  
Owing to its relatively benign safety profile, trabectedin frequently permits patients to benefit 
from an active treatment for prolonged periods and is generally well tolerated, often allowing 
patients to carry on with normal daily activities. 
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Figure Legends 
 
Figure 1. Case 1: Computed tomography (CT) scans after 3 cycles of neoadjuvant 
doxorubicin + ifosfamide showing a 20 cm mixed (fat + fleshy) lesion in the right thoracic 
hemisphere with left side mediastinal shift: a) coronal CT scan; b) axial CT scan. 
 
Figure 2. Case 1: Computed tomography scan showing a) recurrence of two hypodense 
lesions in the thymus, the first in the left superior lobe and the second in the right lobe; and b) 
a complete response in the first lesion and a major response in the second lesion after 9 cycles 
of trabectedin.  
 
Figure 3. Case 2: Axial computed tomography scans in a patient with recurrent myxoid 
liposarcoma: a) before trabectedin; b) after 6 cycles of trabectedin.  
 
Figure 4. Case 2: Axial computed tomography scans in a patient with recurrent myxoid 
liposarcoma a) before rechallenge with trabectedin; b) after rechallenge with 6 cycles of 
trabectedin.  
 
Figure 5. Case 3: Computed tomography scans showing pulmonary metastases in a patient 
with leiomyosarcoma a) during treatment with trabectedin (June 2015); b) at the end of 
treatment with trabectedin (February 2016).  
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Figure 6. Case 3. Computed tomography scans showing an intra-abdominal mass and liver 
metastases in a patient with leiomyosarcoma a) during treatment with trabectedin; b) at the 
end of treatment with trabectedin; c) under third-line (pazopanib) and fourth-line 
(gemcitabine + dacarbazine) therapy.  
 
Figure 7. Case 1 timeline. AE, adverse event; G, grade. 
 
Figure 8. Case 2 timeline. DTIC, dacarbazine; G, grade; Gem, gemcitabine; mo, months; NR, 
no response; PR, partial response; SD, stable disease. 
 
Figure 9. Case 3 timeline. BSC, best supportive care; DTIC, dacarbazine; G, grade; Gem, 
gemcitabine; PR, partial response; SD, stable disease. 
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